Safety of direct oral anticoagulants in patients with advanced liver disease

Georg Semmler, Katharina Pomej, David J. M. Bauer, Lorenz Balcar, Benedikt Simbrunner, Teresa Binter, Lukas Hartl, Jeannette Becker, Matthias Pinter, Peter Quehenberger, Michael Trauner, Mattias Mandorfer, Ton Lisman, Thomas Reiberger*, Bernhard Scheiner

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
15 Downloads (Pure)

Abstract

Background & Aims While direct oral anticoagulants (DOACs) are increasingly used in patients with liver disease, safety data especially in advanced chronic liver disease (ACLD) are limited. Methods Liver disease patients receiving DOAC treatment (ACLD: n = 104; vascular liver disease: n = 29) or vitamin K antagonists (VKA)/low-molecular-weight heparin (LMWH; ACLD: n = 45; vascular: n = 13) between January 2010 and September 2020 were retrospectively included. Invasive procedures and bleeding events were recorded. Calibrated anti-Xa peak levels and thrombomodulin-modified thrombin generation assays (TM-TGAs) were measured in a subgroup of 35/28 DOAC patients. Results Among patients receiving DOAC, 55 (41.3%) had advanced liver dysfunction (Child-Pugh-stage [CPS] B/C) and 66 (49.6%) had experienced decompensation. Overall, 205 procedures were performed in 60 patients and procedure-related bleedings occurred in 7 (11.7%) patients. Additionally, 38 (28.6%) patients experienced spontaneous (15 minor, 23 major) bleedings during a median follow-up of 10.5 (IQR: 4.0-27.8) months. Spontaneous bleedings in ACLD patients were more common in CPS-B/C (at 12 months: 36.9% vs CPS-A: 15.9%, subdistribution hazard ratio [SHR]: 3.23 [95% CI: 1.59-6.58], P < .001), as were major bleedings (at 12 months: 22.0% vs 5.0%, SHR: 5.82 [95% CI: 2.00-16.90], P < .001). Importantly, CPS (adjusted SHR: 4.12 [91% CI: 1.82-9.37], P < .001), but not the presence of hepatocellular carcinoma or varices, was independently associated with major bleeding during DOAC treatment. Additionally, ACLD patients experiencing bleeding had worse overall survival (at 12 months: 88.9% vs 95.0% without bleeding; P < .001). Edoxaban anti-Xa peak levels were higher in patients with CPS-B/C (345 [95% CI: 169-395] vs CPS-A: 137 [95% CI: 96-248] ng/mL, P = .048) and were associated with lower TM-TGA. Importantly, spontaneous bleeding rates were comparable to VKA/LMWH patients. Conclusions Anticoagulants including DOACs should be used with caution in patients with advanced liver disease due to a significant rate of spontaneous bleeding events.

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalLiver International
DOIs
Publication statusE-pub ahead of print - 10-Jul-2021

Keywords

  • ACLD
  • bleeding
  • DOAC
  • edoxaban
  • NOAC
  • vascular liver disease
  • PORTAL-VEIN THROMBOSIS
  • CIRRHOSIS PATIENTS
  • RIVAROXABAN
  • EDOXABAN
  • MULTICENTER
  • GENERATION
  • INHIBITOR
  • APIXABAN
  • WARFARIN
  • THERAPY

Cite this